DE602004011553D1 - Hemmer-darstellende mittel - Google Patents
Hemmer-darstellende mittelInfo
- Publication number
- DE602004011553D1 DE602004011553D1 DE602004011553T DE602004011553T DE602004011553D1 DE 602004011553 D1 DE602004011553 D1 DE 602004011553D1 DE 602004011553 T DE602004011553 T DE 602004011553T DE 602004011553 T DE602004011553 T DE 602004011553T DE 602004011553 D1 DE602004011553 D1 DE 602004011553D1
- Authority
- DE
- Germany
- Prior art keywords
- hemmer
- imaging
- presenting medium
- presenting
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000012216 imaging agent Substances 0.000 abstract 2
- 238000003745 diagnosis Methods 0.000 abstract 1
- 238000002059 diagnostic imaging Methods 0.000 abstract 1
- 238000003384 imaging method Methods 0.000 abstract 1
- 238000011503 in vivo imaging Methods 0.000 abstract 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 abstract 1
- 229940121386 matrix metalloproteinase inhibitor Drugs 0.000 abstract 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 abstract 1
- 229940124530 sulfonamide Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0326546 | 2003-11-14 | ||
| GBGB0326546.9A GB0326546D0 (en) | 2003-11-14 | 2003-11-14 | Inhibitor imaging agents |
| PCT/GB2004/004792 WO2005049005A1 (en) | 2003-11-14 | 2004-11-12 | Inhibitor imaging agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE602004011553D1 true DE602004011553D1 (de) | 2008-03-13 |
| DE602004011553T2 DE602004011553T2 (de) | 2009-03-26 |
Family
ID=29726529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602004011553T Active DE602004011553T2 (de) | 2003-11-14 | 2004-11-12 | Hemmer-darstellende mittel |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20070104644A1 (de) |
| EP (1) | EP1682113B1 (de) |
| JP (1) | JP5043438B2 (de) |
| KR (1) | KR20060118479A (de) |
| CN (1) | CN1901894A (de) |
| AT (1) | ATE384519T1 (de) |
| AU (1) | AU2004290950A1 (de) |
| BR (1) | BRPI0416528A (de) |
| CA (1) | CA2545267A1 (de) |
| DE (1) | DE602004011553T2 (de) |
| ES (1) | ES2299884T3 (de) |
| GB (1) | GB0326546D0 (de) |
| MX (1) | MXPA06005355A (de) |
| NO (1) | NO20062118L (de) |
| RU (1) | RU2006117298A (de) |
| WO (1) | WO2005049005A1 (de) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| WO2007030012A2 (en) * | 2005-09-05 | 2007-03-15 | Stichting Voor De Technische Wetenscahappen | Extracellular matrix imaging |
| FR2891830B1 (fr) | 2005-10-07 | 2011-06-24 | Guerbet Sa | Composes a chaines aminoalcools courtes et complexes metalliques pour l'imagerie medicale |
| GB0520527D0 (en) * | 2005-10-10 | 2005-11-16 | Ge Healthcare Ltd | Automated method |
| ES2357861T3 (es) | 2006-02-15 | 2011-05-03 | Ge Healthcare As | Agentes de contraste. |
| US8247442B2 (en) * | 2006-03-29 | 2012-08-21 | Purdue Pharma L.P. | Benzenesulfonamide compounds and their use |
| ES2471974T3 (es) * | 2006-03-29 | 2014-06-27 | Novartis Ag | Inhibidores selectivos de MMP a base de hidroxamato |
| TW200815353A (en) * | 2006-04-13 | 2008-04-01 | Euro Celtique Sa | Benzenesulfonamide compounds and their use |
| TW200812963A (en) * | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| GB0610395D0 (en) * | 2006-05-25 | 2006-07-05 | Ge Healthcare Ltd | Novel imaging agents |
| JP2010513476A (ja) * | 2006-12-20 | 2010-04-30 | ジーイー・ヘルスケア・アクスイェ・セルスカプ | 造影剤 |
| US8399486B2 (en) * | 2007-04-09 | 2013-03-19 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use thereof |
| WO2009040659A2 (en) * | 2007-09-28 | 2009-04-02 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| EP2119690A1 (de) * | 2008-05-14 | 2009-11-18 | Academisch Medisch Centrum bij de Universiteit van Amsterdam | Radioaktiv markierte MMP-selektive Verbindungen |
| JP5322527B2 (ja) * | 2008-07-17 | 2013-10-23 | 浜松ホトニクス株式会社 | アポトーシスの検出に適した化合物 |
| EP2147684A1 (de) * | 2008-07-22 | 2010-01-27 | Bracco Imaging S.p.A | Selektiv gegen Metallproteasen wirkende Diagnosemittel |
| WO2010138720A2 (en) * | 2009-05-27 | 2010-12-02 | The Scripps Research Institute | Compounds and methods for chelating metals in aqueous solutions |
| WO2011000958A1 (en) * | 2009-07-03 | 2011-01-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compounds targeting the cation-independent mannose 6-phosphate receptor |
| MX2012004900A (es) | 2009-10-29 | 2012-06-14 | Procter & Gamble | Composicion acondicionadora para el cabello que comprende un sistema surfactante cationico, un tinte directo y un espesante no ionico. |
| US9023318B2 (en) * | 2011-06-08 | 2015-05-05 | Siemens Medical Solutions Usa, Inc. | Compounds with matrix-metalloproteinase inhibitory activity and imaging agents thereof |
| US8871189B2 (en) * | 2011-11-30 | 2014-10-28 | Mallinckrodt Llc | MMP-targeted therapeutic and/or diagnostic nanocarriers |
| CN103980277B (zh) * | 2014-05-27 | 2016-06-15 | 青岛大学 | 一种叶酸巯基化衍生物的制备方法 |
| GB202012671D0 (en) * | 2020-08-13 | 2020-09-30 | Nrf Ithemba Labs | Theranostic Compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5714465A (en) * | 1989-05-19 | 1998-02-03 | Amgen Inc. | Method of inhibiting tumor cell dissemination with a metalloproteinase inhibitor |
| US5863949A (en) * | 1995-03-08 | 1999-01-26 | Pfizer Inc | Arylsulfonylamino hydroxamic acid derivatives |
| DE69805473T2 (de) * | 1997-08-08 | 2003-01-16 | Pfizer Prod Inc | Arylsulfonylaminohydroxamsäurederivate |
| US6214872B1 (en) * | 1997-08-08 | 2001-04-10 | Pfizer Inc. | Aryloxyarylsulfonylamino hydroxamic acid derivatives |
| IL127496A0 (en) * | 1997-12-19 | 1999-10-28 | Pfizer Prod Inc | The use of MMP inhibitors for the treatment of ocular angiogenesis |
| DK0952148T3 (da) * | 1998-04-10 | 2004-09-20 | Pfizer Prod Inc | Cyclobutylaryloxyarylsulfonylaminohydroxamsyrederivater |
| TR200202211T2 (tr) * | 1999-08-18 | 2002-11-21 | Warner-Lambert Company | Matris metaloproteinaz inhibitörleri olarak kullanışlı olan hidroksamik asit bileşikleri |
| IL138686A0 (en) * | 1999-10-01 | 2001-10-31 | Pfizer Prod Inc | α- SULFONYLAMINO HYDROXAMIC ACID INHIBITORS OF MATRIX METALLOPROTEINASES FOR THE TREATMENT OF PERIPHERAL OR CENTRAL NERVOUS SYSTEM DISORDERS |
| US6656448B1 (en) * | 2000-02-15 | 2003-12-02 | Bristol-Myers Squibb Pharma Company | Matrix metalloproteinase inhibitors |
| DE60114022T2 (de) * | 2000-05-30 | 2006-07-13 | Board Of Governors Of Wayne State University, Detroit | Matrix metalloproteinase-inhibitoren |
| JP2006519216A (ja) * | 2003-02-10 | 2006-08-24 | ジーイー・ヘルスケア・リミテッド | Ｍｍｐ阻害活性を有する画像診断剤 |
-
2003
- 2003-11-14 GB GBGB0326546.9A patent/GB0326546D0/en not_active Ceased
-
2004
- 2004-11-12 MX MXPA06005355A patent/MXPA06005355A/es unknown
- 2004-11-12 RU RU2006117298/15A patent/RU2006117298A/ru not_active Application Discontinuation
- 2004-11-12 WO PCT/GB2004/004792 patent/WO2005049005A1/en active IP Right Grant
- 2004-11-12 BR BRPI0416528-4A patent/BRPI0416528A/pt not_active IP Right Cessation
- 2004-11-12 AT AT04798512T patent/ATE384519T1/de not_active IP Right Cessation
- 2004-11-12 CA CA002545267A patent/CA2545267A1/en not_active Abandoned
- 2004-11-12 KR KR1020067009293A patent/KR20060118479A/ko not_active Application Discontinuation
- 2004-11-12 CN CNA2004800403628A patent/CN1901894A/zh active Pending
- 2004-11-12 AU AU2004290950A patent/AU2004290950A1/en not_active Abandoned
- 2004-11-12 DE DE602004011553T patent/DE602004011553T2/de active Active
- 2004-11-12 EP EP04798512A patent/EP1682113B1/de not_active Not-in-force
- 2004-11-12 JP JP2006538954A patent/JP5043438B2/ja not_active Expired - Fee Related
- 2004-11-12 US US10/560,371 patent/US20070104644A1/en not_active Abandoned
- 2004-11-12 ES ES04798512T patent/ES2299884T3/es active Active
-
2006
- 2006-05-11 NO NO20062118A patent/NO20062118L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005049005A1 (en) | 2005-06-02 |
| EP1682113A1 (de) | 2006-07-26 |
| AU2004290950A1 (en) | 2005-06-02 |
| CN1901894A (zh) | 2007-01-24 |
| RU2006117298A (ru) | 2007-12-20 |
| KR20060118479A (ko) | 2006-11-23 |
| JP5043438B2 (ja) | 2012-10-10 |
| EP1682113B1 (de) | 2008-01-23 |
| ES2299884T3 (es) | 2008-06-01 |
| NO20062118L (no) | 2006-05-11 |
| JP2007511494A (ja) | 2007-05-10 |
| MXPA06005355A (es) | 2006-07-10 |
| DE602004011553T2 (de) | 2009-03-26 |
| BRPI0416528A (pt) | 2007-01-09 |
| GB0326546D0 (en) | 2003-12-17 |
| CA2545267A1 (en) | 2005-06-02 |
| ATE384519T1 (de) | 2008-02-15 |
| US20070104644A1 (en) | 2007-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004011553D1 (de) | Hemmer-darstellende mittel | |
| MX2007003518A (es) | Agentes formadores de imagenes de inhibidor de metaloproteinasa. | |
| EP1547996A4 (de) | Diagnostische sonden und heilmittel für krankheiten, bei denen prionprotein akkumuliert wird, und anfürbereagenzien für prionprotein | |
| DK1472541T3 (da) | Afbildningsmidler og metoder til at afbilde NAALADase og PSMA | |
| BRPI0507684B8 (pt) | agentes de contraste para imagem de perfusão miocárdica | |
| ATE494041T1 (de) | Gewebe-haltesystem für medizinische ultraschallbehandlung | |
| ATE349446T1 (de) | Amyloid plaque aggregationshemmer und diagnostische bilderzeugungsmittel | |
| WO2005027733A3 (en) | Biological markers for diagnosing multiple sclerosis | |
| DK1530724T3 (da) | Diagnose og forebyggelse af cancercelleinvasion | |
| ATE539069T1 (de) | Isotopenmarkierte benzofuranverbindungen als bilddarstellende mittel für amyloidogene proteine | |
| CY1108540T1 (el) | Ταυτοποιηση θεραπευτικων ενωσεων | |
| DE50207866D1 (de) | Verwendung löslicher cytokeratin-1-fragmente in diagnostik | |
| ATE451477T1 (de) | Diagnose und überwachung von hepatozellulärem karzinom | |
| PL374188A1 (en) | Medium for contrast enhancement use for ultrasonic, endoscopic and other medical examinations | |
| NO20054049D0 (no) | Fremgangsmate for diagnose og behandling. | |
| NO20030115D0 (no) | Kontrastmiddel | |
| ITMI20011706A0 (it) | Agenti di contrasto radiografici ionici e non ionici, utilizzabili per l'indagine diagnostica combinata tramite raggi-x e risonanza magnetic | |
| IL159479A (en) | Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis | |
| FR2845267B1 (fr) | Kit cutane de diagnostic de l'atopie | |
| ITRM20020244A1 (it) | Dispositivo integrato per l'esecuzione di un'indagine genetica e relativa apparecchiatura di esame e lettura. | |
| WO2007070827A3 (en) | Contrast agents for myocardium perfusion imaging | |
| ITMI20021976A1 (it) | Procedimento e dispositivo per la diagnosi di uno smorzatore di pressioni. | |
| ATE337020T1 (de) | Fettsaure analoge zur diagnose von kranzarterie erkrankungen | |
| ITFI20020176A1 (it) | Immunoglobulina specifica per callicreina tessutale umana, formulazione immunologica comprendente detta immunoglobulina e relativo kit diagnostico per la diagnosi dell'ischemia cerebrale. | |
| Thet | Diagnostic significance of Tc-99m tetrofosmin washout for hypertrophic cardiomyopathy: clinical and basic investigation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition | ||
| 8328 | Change in the person/name/address of the agent |
Representative=s name: HAMMONDS LLP, LONDON, GB |
|
| R082 | Change of representative |
Ref document number: 1682113 Country of ref document: EP Representative=s name: J D REYNOLDS & CO., GB |